Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 3;386(5):492-494.
doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Ital Nemet  1 , Limor Kliker  1 , Yaniv Lustig  1 , Neta Zuckerman  1 , Oran Erster  1 , Carmit Cohen  2 , Yitshak Kreiss  2 , Sharon Alroy-Preis  3 , Gili Regev-Yochay  2 , Ella Mendelson  4 , Michal Mandelboim  4
Affiliations

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Ital Nemet et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralization Efficiency against Wild-Type Virus and the Beta, Delta, and Omicron Variants of Concern.
Serum samples were obtained from 20 health care workers who had received two doses of the BNT162b2 vaccine (Panels A and B) and from 20 who had received three doses (Panels C and D). Samples were tested by microneutralization against wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the B.1.351 (beta), B.1.617.2 (delta), and B.1.1.529 (omicron) variants of concern. Dashed lines in Panels A and C indicate the cutoff titer. Geometric mean titers (horizontal lines) with 95% confidence intervals (𝙸 bars) are presented, as well as the geometric mean titer value. Dots indicate individual serum samples. The factor reduction as compared with wild-type virus is shown for samples obtained from participants who had received two doses of vaccine (Panel B) and those obtained from participants who had received three doses (Panel D). For these analyses, the mean factor differences between wild-type SARS-CoV-2 and the variants of concern were calculated for each participant; the means of the individual values are shown here. Error bars in Panels B and D indicate the standard error.
See this image and copyright information in PMC

References

    1. World Health Organization. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. November 26, 2021. (https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1....).
    1. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021;385:1393-1400. - PMC - PubMed
    1. Haas EJ, McLaughlin JM, Khan F, et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis 2021. September 22 (Epub ahead of print). - PMC - PubMed

MeSH terms

Supplementary concepts